Immix Biopharma, Inc.

Immix Biopharma, Inc. announced the termination of Richard Graydon, effective July 17, 2026. The company stated that the termination was for reasons unrelated to his activities at the company. Management believes that due to his short tenure, there will be no material effect on the business.

Immix Biopharma, Inc. announced the closing of its previously announced underwritten registered offering, raising approximately $140.65 million in net proceeds. The offering involved 16,778,524 shares of common stock at a price of $8.94 per share. This financing included leading U.S. biotechnology institutional investors and mutual funds, providing capital to support ImmixBio's position as a global leader in AL Amyloidosis and the development of its lead candidate NXC-201.

Immix Biopharma, Inc. announced the pricing of an underwritten public offering of 16,778,524 shares of its common stock at $8.94 per share. The offering is expected to generate gross proceeds of $150 million, with estimated net proceeds of approximately $140.65 million. The company plans to use these funds for NXC-201 development, working capital, and general corporate purposes, which is anticipated to extend its operational runway into mid-2028.

Immix Biopharma, Inc. announced the pricing of an underwritten registered offering of 16,778,524 shares of its common stock at $8.94 per share. The offering is expected to generate gross proceeds of $150 million and is anticipated to close around May 22, 2026. Immix intends to use the net proceeds to fund NXC-201 development, working capital, and general corporate purposes, which is expected to meet the company's operational needs into mid-2028.

Immix Biopharma announced a significant update from its Phase 2 NEXICART-2 NXC-201 clinical trial for relapsed/refractory AL Amyloidosis, reporting a 95% complete response (CR) rate among the first 20 patients. All four MRD-negative patients previously highlighted at ASH 2025 have now converted to CR, with no relapses observed to date. The company plans to initiate a multi-center, randomized Phase 3 trial for NXC-201 in newly diagnosed AL Amyloidosis patients in the first half of 2027, with the next NEXICART-2 update expected in late September 2026.

Immix Biopharma announced strong results from its NEXICART-2 Phase 2 clinical trial for NXC-201 in relapsed/refractory AL Amyloidosis. The complete response (CR) rate reached 95% (19 of 20 patients), with all four previously MRD-negative patients converting to CR. No relapses have been observed for patients who reached CR, and all subsequently enrolled patients with available MRD results are MRD-negative at one month. The company plans to initiate a Phase 3 trial and expects to present 1-year follow-up data by March 2027, aiming for BLA submission and commercial launch.

Immix Biopharma reported a net loss of $10.1 million for the first quarter of 2026, significantly wider than the $4.5 million loss in Q1 2025, primarily due to increased research and development and general and administrative expenses. The company's cash, cash equivalents, and short-term investments stood at $90.6 million as of March 31, 2026, and it believes these funds are sufficient for at least the next 12 months. Immix Biopharma also increased its At The Market offering capacity to $100 million.